Change in COVID-19 risk over time following vaccination with CoronaVac: A testnegative case-control study

OBJECTIVE: To estimate the change in odds of covid-19 over time following primary series completion of the inactivated whole virus vaccine, CoronaVac (Sinovac Biotech) in São Paulo state, Brazil. DESIGN: Test negative case-control study. SETTING: Community testing for covid-19 in São Paulo state, Br...

Descripción completa

Detalles Bibliográficos
Autores principales: Hitchings, Matt D.T., Ranzani, Otavio T., Lind, Margaret L., Dorion, Murilo, D’Agostini, Tatiana Lang, de Paula, Regiane Cardoso, de Paula, Olivia Ferreira Pereira, de Moura Villela, Edlaine Faria, Torres, Mario Sergio Scaramuzzini, de Oliveira, Silvano Barbosa, Schulz, Wade, Almiron, Maria, Said, Rodrigo, de Oliveira, Roberto Dias, da Silva, Patricia Vieira, de Araújo, Wildo Navegantes, Gorinchteyn, Jean Carlo, Dean, Natalie E., Andrews, Jason R., Cummings, Derek A.T., Ko, Albert I., Croda, Julio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728874/
https://www.ncbi.nlm.nih.gov/pubmed/34988559
http://dx.doi.org/10.1101/2021.12.23.21268335
Descripción
Sumario:OBJECTIVE: To estimate the change in odds of covid-19 over time following primary series completion of the inactivated whole virus vaccine, CoronaVac (Sinovac Biotech) in São Paulo state, Brazil. DESIGN: Test negative case-control study. SETTING: Community testing for covid-19 in São Paulo state, Brazil. PARTICIPANTS: Adults aged 18–120 years who were residents of São Paulo state, without a previous laboratory-confirmed covid-19 infection, who received only two doses of CoronaVac, and underwent reverse transcription polymerase chain reaction (RT-PCR) testing for SARS-CoV-2 from 17 January to 30 September 2021. MAIN OUTCOME MEASURES: RT-PCR-confirmed symptomatic covid-19 and associated hospital admissions and deaths. Cases were pair-matched to test-negative controls by age (in 5-year bands), municipality of residence, healthcare worker (HCW) status, and date of RT-PCR test (±3 days). Conditional logistic regression was adjusted for sex, number of covid-19-associated comorbidities, race, and previous acute respiratory infection. RESULTS: From 137,820 eligible individuals, 37,929 cases with symptomatic covid-19 and 25,756 test-negative controls with covid-19 symptoms were formed into 37,929 matched pairs. Adjusted odds ratios of symptomatic covid-19 increased with time since series completion, and this increase was greater in younger individuals, and among HCWs compared to non-HCWs. Adjusted odds ratios of covid-19 hospitalisation or death were significantly increased from 98 days since series completion, compared to individuals vaccinated 14–41 days previously: 1.40 (95% confidence interval 1.09 to 1.79) from 98–125 days, 1.55 (1.16 to 2.07) from 126–153 days, 1.56 (1.12 to 2.18) from 154–181 days, and 2.12 (1.39–3.22) from 182 days. CONCLUSIONS: In the general population of São Paulo state, Brazil, an increase in odds of moderate and severe covid-19 outcomes was observed over time following primary series completion with CoronaVac.

Ejemplares similares